Anistreplase

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Anistreplase
Clinical data
Trade names Eminase
AHFS/Drugs.com Micromedex Detailed Consumer Information
Pharmacokinetic data
Half-life 90 minutes
Identifiers
81669-57-0 YesY
B01AD03
DrugBank DB00029 YesY
KEGG D02947 YesY
Chemical data
approx. 131,000 g/mol
 YesY (what is this?)  (verify)

Anistreplase is a thrombolytic drug.[1][2][3]

Anistreplase has been developed by Beecham as Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC)

Mechanism[edit]

It is a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the enzyme's active site. When the drug is administered, the acyl group gets hydrolyzed, thereby freeing the activator complex. It converts plasminogen to plasmin, which in turn degrades fibrin (blood clots) to fibrin split products.

References[edit]